Roivant Sciences and its joint venture Priovant Therapeutics announced Friday that the U.S. Food and Drug Administration has approved Lisraya (brepocitinib) as the first oral, targeted treatment for dermatomyositis, a rare autoimmune disease that causes painful skin rashes and progressive muscle weakness. The companies set a list price of $35,000 for a 30‑day supply, positioning the drug among the most expensive therapies for rare conditions.
Key Details of the Approval
Lisraya is administered as a daily pill containing 30 mg of brepocitinib. In the pivotal trial, patients receiving Lisraya achieved a mean total improvement score of 46.5 after 52 weeks, compared with 31.2 for those on placebo. The difference was statistically significant, and benefits were observed as early as week four.
Patient Access and Support
Priovant CEO Ben Zimmer said that prescribing is now open and the first patient prescriptions have already been filled. To help mitigate the high price, the companies are launching a patient‑support program that can reduce out‑of‑pocket costs to zero for eligible patients, though eligibility criteria were not disclosed.
Financial Outlook
Roivant CEO Matt Gline estimated the net annual value to the company per patient on a full year of therapy to be in the low‑to‑mid $300,000 range. He cautioned that market adoption is expected to build gradually as physicians and patients become familiar with the new option.
Ownership Structure and Market Exclusivity
Pfizer originally licensed the drug to Priovant in 2021, creating the joint venture with Roivant. Roivant now holds a 71 % stake in Priovant, while Pfizer retains a 24 % interest. According to the National Institutes of Health, fewer than 5,000 Americans are affected by dermatomyositis, underscoring the limited patient pool for this therapy. The partners expect Lisraya to retain U.S. market exclusivity until at least 2039.
Implications for Patients and the Healthcare System
The approval offers a new therapeutic avenue for a disease that has long lacked targeted oral treatments. However, the steep price tag raises questions about affordability and insurance coverage, even with the support program in place. Stakeholders—including physicians, insurers, and patient advocacy groups—will be watching how quickly the drug is adopted and how reimbursement pathways evolve.
For families dealing with dermatomyositis, Lisraya represents a hopeful development, but navigating the cost and insurance landscape will be a critical next step. The companies have pledged to work with providers and payers to ensure that eligible patients can access the medication without financial hardship.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
